title: Quantitative expression of erythropoietin receptor (EPO-R) on acute leukaemia cells: relationships between the amount of EPO-R and CD phenotypes, in vitro proliferative response, the amount of other cytokine receptors and clinical prognosis. Japan Adult Leukaemia Study Group.
abstract: Expression of erythropoietin (EPO) receptor (EPO-R) was analysed in leukaemia cells from 150 patients with acute myeloid leukaemia (AML) or acute lymphoblastic leukaemia (ALL). EPO-R was expressed in 81 (60%) out of 136 AML, and in vitro treatment with EPO led to proliferation of leukaemia cells in 13 (16%) out of 81 AML examined. EPO-R expression and in vitro response to EPO were observed in all subtypes of AML according to the French-American-British (FAB) classification. All eight patients with FAB-M6 expressed EPO-R, and one out of four showed an in vitro response to EPO. Although there was no significant correlation (r = 0.2522) between the amount of EPO-R and the in vitro response to EPO, all of the AML patients who showed in vitro response expressed EPO-R. Stem cell factor significantly enhanced both EPO-R expression and in vitro response to EPO. Interleukin-3 tended to increase in vitro response to EPO. CD phenotypes, the amount of granulocyte colony-stimulating factor (G-CSF) receptors and the amount of TPO receptors had no significant relationship with the amount of EPO-R. Patients with both EPO-R expression and in vitro response to EPO had shorter duration of complete remission than those without EPO-R (P = 0.0053). EPO-R was expressed in four (29%) out of 14 ALL, and none out of five ALL showed in vitro response to EPO.
authors.affiliation: Department of Medicine III, Hamamatsu University School of Medicine, Hamamatsu, Japan.
authors.forename: A
authors.initials: A
authors.lastname: Takeshita
authors.forename: K
authors.initials: K
authors.lastname: Shinjo
authors.forename: M
authors.initials: M
authors.lastname: Higuchi
authors.forename: S
authors.initials: S
authors.lastname: Miyawaki
authors.forename: Y
authors.initials: Y
authors.lastname: Takemoto
authors.forename: Y
authors.initials: Y
authors.lastname: Kishimoto
authors.forename: K
authors.initials: K
authors.lastname: Saito
authors.forename: H
authors.initials: H
authors.lastname: Takuchi
authors.forename: K
authors.initials: K
authors.lastname: Kuriyama
authors.forename: Y
authors.initials: Y
authors.lastname: Kimura
authors.forename: N
authors.initials: N
authors.lastname: Asou
authors.forename: M
authors.initials: M
authors.lastname: Takahashi
authors.forename: T
authors.initials: T
authors.lastname: Hotta
authors.forename: A
authors.initials: A
authors.lastname: Kanamaru
authors.forename: R
authors.initials: R
authors.lastname: Ueda
authors.forename: R
authors.initials: R
authors.lastname: Ohno
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D002455:Cell Division; D016207:Cytokines / Q000494:pharmacology; D005260:Female; D006801:Humans; D007951:Leukemia, Myeloid / Q000378:metabolism* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009363:Neoplasm Proteins; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000378:metabolism* / Q000473:pathology; D011379:Prognosis; D011518:Proto-Oncogene Proteins / Q000378:metabolism; D018121:Receptors, Cytokine; D017467:Receptors, Erythropoietin / Q000378:metabolism*; D016188:Receptors, Granulocyte Colony-Stimulating Factor / Q000378:metabolism; D053628:Receptors, Thrombopoietin
chemical_list: D016207:Cytokines; D009363:Neoplasm Proteins; D011518:Proto-Oncogene Proteins; D018121:Receptors, Cytokine; D017467:Receptors, Erythropoietin; D016188:Receptors, Granulocyte Colony-Stimulating Factor; D053628:Receptors, Thrombopoietin; C082218:MPL protein, human